Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall St slips as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- Qualcomm to issue warrant to Amazon for up to 25M shares
- Trump says Canada's Bombardier must build jets in US or lose market access
- Wall St slips as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat
February 13, 2020 4:04 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.62), $0.03 better than the analyst estimate of ($1.65). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.15 million.
In 2019 we created a substantial foundation based on the strong launch of Crysvita and the validation of our gene therapy platform across multiple clinical programs, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of... More
